These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35211015)

  • 1. Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.
    Jackson-Patel V; Liu E; Bull MR; Ashoorzadeh A; Bogle G; Wolfram A; Hicks KO; Smaill JB; Patterson AV
    Front Pharmacol; 2022; 13():803602. PubMed ID: 35211015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
    Hong CR; Mehta SY; Liyanage HDS; McManaway SP; Lee HH; Jaiswal JK; Bogle G; Tercel M; Pruijn FB; Wilson WR; Hicks KO
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):673-687. PubMed ID: 34245333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
    Foehrenbacher A; Patel K; Abbattista MR; Guise CP; Secomb TW; Wilson WR; Hicks KO
    Front Oncol; 2013; 3():263. PubMed ID: 24109591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.
    Hong CR; Bogle G; Wang J; Patel K; Pruijn FB; Wilson WR; Hicks KO
    Front Pharmacol; 2018; 9():1013. PubMed ID: 30279659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
    Foehrenbacher A; Secomb TW; Wilson WR; Hicks KO
    Front Oncol; 2013 Dec; 3():314. PubMed ID: 24409417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
    Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids.
    Mao X; McManaway S; Jaiswal JK; Patel PB; Wilson WR; Hicks KO; Bogle G
    PLoS Comput Biol; 2018 Oct; 14(10):e1006469. PubMed ID: 30356233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.
    Wong WW; Jackson RK; Liew LP; Dickson BD; Cheng GJ; Lipert B; Gu Y; Hunter FW; Wilson WR; Hay MP
    Biochem Pharmacol; 2019 Nov; 169():113641. PubMed ID: 31541630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
    Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
    Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
    Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
    Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
    Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.
    Ashoorzadeh A; Mowday AM; Abbattista MR; Guise CP; Bull MR; Silva S; Patterson AV; Smaill JB
    ACS Med Chem Lett; 2023 Nov; 14(11):1517-1523. PubMed ID: 37974941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.
    Gu Y; Patterson AV; Atwell GJ; Chernikova SB; Brown JM; Thompson LH; Wilson WR
    Mol Cancer Ther; 2009 Jun; 8(6):1714-23. PubMed ID: 19509245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
    Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.
    Jameson MB; Rischin D; Pegram M; Gutheil J; Patterson AV; Denny WA; Wilson WR
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):791-801. PubMed ID: 20012293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
    Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
    Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.